Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes

Diabetes Care. 2007 May;30(5):1261-3. doi: 10.2337/dc06-2208. Epub 2007 Feb 15.

Authors

Francesca Porcellati¹, Paolo Rossetti, Natalia Busciantella Ricci, Simone Pampanelli, Elisabetta Torlone, Susana Hernandez Campos, Anna Marinelli Andreoli, Geremia B Bolli, Carmine G Fanelli

Affiliation

¹ University of Perugia, Department of Internal Medicine, Section of Internal Medicine, Endocrinology, and Metabolism, via E. Dal Pozzo, 06126 Perugia, Italy.

PMID: 17303785
DOI: 10.2337/dc06-2208

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Blood Glucose / drug effects
Blood Glucose / metabolism
Diabetes Mellitus, Type 1 / drug therapy*
Drug Administration Schedule
Female
Humans
Hypoglycemic Agents / administration & dosage
Hypoglycemic Agents / pharmacokinetics
Hypoglycemic Agents / therapeutic use
Injections, Subcutaneous
Insulin / administration & dosage
Insulin / analogs & derivatives*
Insulin / blood
Insulin / pharmacokinetics
Insulin / therapeutic use
Insulin Glargine
Insulin, Long-Acting
Male
Time Factors

Substances

Blood Glucose
Hypoglycemic Agents
Insulin
Insulin, Long-Acting
Insulin Glargine